Global API micronization market set to surge 49% by 2030, led by specialized industry pioneers

Data Compilation
#PharmaFlow

Pipeline Prospector August 2025: Novo’s Wegovy approved for MASH, Tonix Pharma’s fibromyalgia drug okayed

Stock Recap
#PipelineProspector

DSSTox_CID_3557

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

17 API Suppliers, 14 USDMF, 6 CEP/COS, 1 JDMF, 1 EU WC, 5 NDC API, 4 Listed Suppliers

DEVELOPMENTS

331 Drugs in Development

331 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

124 FDF Dossiers, 28 FDA Orange Book, 81 Europe, 4 Canada, 3 Australia, 3 South Africa, 5 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;ORAL - 40MG/ML

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 2 Rochem International Inc, 18 SPI Pharma, 10 DKSH, 8 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 5 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 5 Kirsch Pharma, 4 ACG Worldwide, 10 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 31 BASF, 1 CD Formulation, 11 Corel Pharma Chem, 6 DFE Pharma, 1 Esteem Industries, 3 Finar, 12 Gangwal Chemicals, 5 Ideal Cures, 5 Ingredion Pharma Solutions, 22 Kerry, 3 Keval Exports, 4 Kima Chemical, 6 Lonza Capsugel, 14 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 4 Novo Excipients, 4 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 29 Roquette, 14 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 3 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

79 Fillers, Diluents & Binders, 52 Coating Systems & Additives, 44 Disintegrants & Superdisintegrants, 37 Direct Compression, 34 Granulation, 34 Thickeners and Stabilizers, 28 Controlled & Modified Release, 28 Parenteral, 27 Solubilizers, 25 Taste Masking, 23 Film Formers & Plasticizers, 21 Chewable & Orodispersible Aids, 20 Topical, 17 Lubricants & Glidants, 15 Co-Processed Excipients, 9 Empty Capsules, 8 Emulsifying Agents, 7 API Stability Enhancers, 6 Rheology Modifiers, 5 Coloring Agents, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents, 1 Soft Gelatin

DIGITAL CONTENT

27 News #PharmaBuzz

27 News #PharmaBuzz

GLOBAL SALES INFORMATION

5 US Medicaid Prescriptions, 62 Regulatory FDF Prices, 1 Annual Reports

MARKET PLACE

4 APIs, 6 FDF Dossiers

PATENTS & EXCLUSIVITIES

141 Health Canada Patents

141 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 5 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

Xls download

Filters

List of Suppliers

Reset Filter

Price Info

Product Main Page

Last Updated on PharmaCompass	Virtual Booth	Country	Name of the Firm	Written Confirmation No.	Product Name	Issue Date	Valid Till	Address of the Firm
06/09/2025	Aurobindo Pharma Limited	India	M/s. Apitoria Pharma Private Limited	WC-0120	Ribavirin Ph. Eur	07-11-2025	07-02-2028	UNIT -I, Sy.Nos. 379, 385, 386, 388 to 396, Borpatla Village, Hathnoora Mandal, Sangareddy District -502296, Telangana State, India.

DSSTox_CID_3557

DSSTox_CID_3557

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

17 API Suppliers

14 USDMF

6 CEP/COS

1 JDMF

1 EU WC

5 NDC API

4 Listed Suppliers

DEVELOPMENTS

331 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

124 FDF Dossiers

28 FDA Orange Book

81 Europe

4 Canada

3 Australia

3 South Africa

5 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;ORAL - 40MG/ML

RELATED EXCIPIENT COMPANIES

2 EUROAPI

2 Rochem International Inc

18 SPI Pharma

10 DKSH

8 Boai NKY Pharmaceuticals Ltd

7 Gangwal Healthcare

5 Nanjing Well Pharmaceutical

2 Pfanstiehl

5 Kirsch Pharma

4 ACG Worldwide

10 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

31 BASF

1 CD Formulation

11 Corel Pharma Chem

6 DFE Pharma

1 Esteem Industries

3 Finar

12 Gangwal Chemicals

5 Ideal Cures

5 Ingredion Pharma Solutions

22 Kerry

3 Keval Exports

4 Kima Chemical

6 Lonza Capsugel

14 Microlex e.U

1 Nanjing Bold Chemical

2 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

4 Novo Excipients

4 Pharmatrans-Sanaq

8 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

29 Roquette

14 Seppic

7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

2 Shijiazhuang Huaxu Pharmaceutical

11 Sigachi Industries

4 Silverline Chemicals

3 The Dow Chemical Company

2 Ulanqab Kema New Material

1 Valens Pharmachem

CAPSULE;ORAL - 200MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 200MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 400MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons